改善动物福利和减少用于人类疫苗效力试验的动物:科学现状和未来方向

Warren Casey , Michael Schmitt , Richard McFarland , Richard Isbrucker , Robin Levis , Juan Arciniega , Johan Descamps , Theresa Finn , Coenraad Hendriksen , Yoshinobu Horiuchi , James Keller , Hajime Kojima , Dorothea Sesardic , Paul Stickings , Nelson W Johnson , Elizabeth Lipscomb , David Allen
{"title":"改善动物福利和减少用于人类疫苗效力试验的动物:科学现状和未来方向","authors":"Warren Casey ,&nbsp;Michael Schmitt ,&nbsp;Richard McFarland ,&nbsp;Richard Isbrucker ,&nbsp;Robin Levis ,&nbsp;Juan Arciniega ,&nbsp;Johan Descamps ,&nbsp;Theresa Finn ,&nbsp;Coenraad Hendriksen ,&nbsp;Yoshinobu Horiuchi ,&nbsp;James Keller ,&nbsp;Hajime Kojima ,&nbsp;Dorothea Sesardic ,&nbsp;Paul Stickings ,&nbsp;Nelson W Johnson ,&nbsp;Elizabeth Lipscomb ,&nbsp;David Allen","doi":"10.1016/j.provac.2011.10.003","DOIUrl":null,"url":null,"abstract":"<div><p>NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. Topics were addressed in detail by speakers and workshop participants and are reported in a series of six reports. This workshop report, the third in the series, addresses methods and strategies for human vaccine potency testing that can refine animal use to lessen pain and distress, improve animal welfare, and reduce animal use. Workshop participants agreed that the following potency tests for human vaccines should have the highest priority for development of reduction and/or refinement methods: (1) potency tests for vaccines that are most commonly used, (2) potency tests that require the largest number of animals, (3) potency tests that cause severe animal pain and distress, (4) tests where the knowledge base of each antigen is advanced, and (5) potency tests for which alternative methods already exist or are in development. Based on these criteria, the highest-priority human vaccines were identified as diphtheria and tetanus vaccines, pertussis vaccines (whole cell and acellular), rabies vaccine, anthrax vaccine, and complex combination vaccines (containing diphtheria, tetanus, and pertussis together with other antigens such as IPV, Hib, and HepB). For successful implementation of reduction and refinement alternatives, further research is required into the development and broader use of humane endpoints, serological potency methods, and approaches that would reduce the number of animals used in currently approved potency assays. Because the workshop focused on both human and veterinary vaccines, workshop participants also recommended that human vaccine potency testing methods for rabies and tetanus be reviewed for their potential application to the corresponding veterinary vaccines. Participants agreed that achieving broader acceptance and use of alternative methods, requires that the general principles and procedures for the validation of alternative methods for vaccines be standardized/harmonized internationally. The research, development, validation, and harmonization activities recommended at this workshop are expected to lead to new reduction and/or refinement of animal use in human vaccine potency testing methods and more widespread adoption of existing methods that can reduce animal use and improve animal welfare while ensuring the continued safety and efficacy of human vaccines.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"5 ","pages":"Pages 33-46"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2011.10.003","citationCount":"19","resultStr":"{\"title\":\"Improving animal welfare and reducing animal use for human vaccine potency testing: state of the science and future directions\",\"authors\":\"Warren Casey ,&nbsp;Michael Schmitt ,&nbsp;Richard McFarland ,&nbsp;Richard Isbrucker ,&nbsp;Robin Levis ,&nbsp;Juan Arciniega ,&nbsp;Johan Descamps ,&nbsp;Theresa Finn ,&nbsp;Coenraad Hendriksen ,&nbsp;Yoshinobu Horiuchi ,&nbsp;James Keller ,&nbsp;Hajime Kojima ,&nbsp;Dorothea Sesardic ,&nbsp;Paul Stickings ,&nbsp;Nelson W Johnson ,&nbsp;Elizabeth Lipscomb ,&nbsp;David Allen\",\"doi\":\"10.1016/j.provac.2011.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. Topics were addressed in detail by speakers and workshop participants and are reported in a series of six reports. This workshop report, the third in the series, addresses methods and strategies for human vaccine potency testing that can refine animal use to lessen pain and distress, improve animal welfare, and reduce animal use. Workshop participants agreed that the following potency tests for human vaccines should have the highest priority for development of reduction and/or refinement methods: (1) potency tests for vaccines that are most commonly used, (2) potency tests that require the largest number of animals, (3) potency tests that cause severe animal pain and distress, (4) tests where the knowledge base of each antigen is advanced, and (5) potency tests for which alternative methods already exist or are in development. Based on these criteria, the highest-priority human vaccines were identified as diphtheria and tetanus vaccines, pertussis vaccines (whole cell and acellular), rabies vaccine, anthrax vaccine, and complex combination vaccines (containing diphtheria, tetanus, and pertussis together with other antigens such as IPV, Hib, and HepB). For successful implementation of reduction and refinement alternatives, further research is required into the development and broader use of humane endpoints, serological potency methods, and approaches that would reduce the number of animals used in currently approved potency assays. Because the workshop focused on both human and veterinary vaccines, workshop participants also recommended that human vaccine potency testing methods for rabies and tetanus be reviewed for their potential application to the corresponding veterinary vaccines. Participants agreed that achieving broader acceptance and use of alternative methods, requires that the general principles and procedures for the validation of alternative methods for vaccines be standardized/harmonized internationally. The research, development, validation, and harmonization activities recommended at this workshop are expected to lead to new reduction and/or refinement of animal use in human vaccine potency testing methods and more widespread adoption of existing methods that can reduce animal use and improve animal welfare while ensuring the continued safety and efficacy of human vaccines.</p></div>\",\"PeriodicalId\":89221,\"journal\":{\"name\":\"Procedia in vaccinology\",\"volume\":\"5 \",\"pages\":\"Pages 33-46\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.provac.2011.10.003\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Procedia in vaccinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877282X1100021X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Procedia in vaccinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877282X1100021X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 19

摘要

NICEATM和iccvm召开了一次国际讲习班,审查人用和兽用疫苗效力和安全性测试方法的科学现状,并确定推进可进一步减少、改进和取代动物使用的新改进方法的机会。发言者和讲习班与会者详细讨论了专题,并在一系列六份报告中作了报告。本研讨会报告是该系列的第三份报告,讨论了人类疫苗效力测试的方法和策略,这些方法和策略可以改进动物使用,以减轻疼痛和痛苦,改善动物福利,并减少动物使用。讲习班与会者一致认为,在开发减少和(或)改进方法方面,应优先考虑下列人用疫苗效力试验:(1)最常用疫苗的效力试验,(2)需要最多动物的效力试验,(3)引起动物严重疼痛和痛苦的效力试验,(4)每种抗原的知识基础较先进的效力试验,以及(5)已经存在或正在开发替代方法的效力试验。根据这些标准,最优先的人类疫苗被确定为白喉和破伤风疫苗、百日咳疫苗(全细胞和非细胞)、狂犬病疫苗、炭疽疫苗和复杂联合疫苗(含白喉、破伤风和百日咳以及其他抗原,如IPV、Hib和HepB)。为了成功实施还原和精炼替代方案,需要进一步研究开发和更广泛地使用人道终点、血清学效价方法,以及减少目前批准的效价测定中使用的动物数量的方法。由于讲习班的重点是人用疫苗和兽用疫苗,讲习班与会者还建议审查狂犬病和破伤风人用疫苗效力测试方法,看其是否可能应用于相应的兽用疫苗。与会者一致认为,要使替代方法得到更广泛的接受和使用,就需要在国际上标准化/统一验证疫苗替代方法的一般原则和程序。本次研讨会建议的研究、开发、验证和协调活动预计将导致新的减少和/或改进人用疫苗效力测试方法中的动物使用,并更广泛地采用可以减少动物使用和改善动物福利的现有方法,同时确保人用疫苗的持续安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Improving animal welfare and reducing animal use for human vaccine potency testing: state of the science and future directions

NICEATM and ICCVAM convened an international workshop to review the state of the science of human and veterinary vaccine potency and safety testing methods and to identify opportunities to advance new and improved methods that can further reduce, refine, and replace animal use. Topics were addressed in detail by speakers and workshop participants and are reported in a series of six reports. This workshop report, the third in the series, addresses methods and strategies for human vaccine potency testing that can refine animal use to lessen pain and distress, improve animal welfare, and reduce animal use. Workshop participants agreed that the following potency tests for human vaccines should have the highest priority for development of reduction and/or refinement methods: (1) potency tests for vaccines that are most commonly used, (2) potency tests that require the largest number of animals, (3) potency tests that cause severe animal pain and distress, (4) tests where the knowledge base of each antigen is advanced, and (5) potency tests for which alternative methods already exist or are in development. Based on these criteria, the highest-priority human vaccines were identified as diphtheria and tetanus vaccines, pertussis vaccines (whole cell and acellular), rabies vaccine, anthrax vaccine, and complex combination vaccines (containing diphtheria, tetanus, and pertussis together with other antigens such as IPV, Hib, and HepB). For successful implementation of reduction and refinement alternatives, further research is required into the development and broader use of humane endpoints, serological potency methods, and approaches that would reduce the number of animals used in currently approved potency assays. Because the workshop focused on both human and veterinary vaccines, workshop participants also recommended that human vaccine potency testing methods for rabies and tetanus be reviewed for their potential application to the corresponding veterinary vaccines. Participants agreed that achieving broader acceptance and use of alternative methods, requires that the general principles and procedures for the validation of alternative methods for vaccines be standardized/harmonized internationally. The research, development, validation, and harmonization activities recommended at this workshop are expected to lead to new reduction and/or refinement of animal use in human vaccine potency testing methods and more widespread adoption of existing methods that can reduce animal use and improve animal welfare while ensuring the continued safety and efficacy of human vaccines.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信